Unknown

Dataset Information

0

Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.


ABSTRACT: Despite widespread use of proton pump inhibitors (PPIs), the incidence of esophageal adenocarcinoma (EAC) continues to rise. PPIs reduce reflux acidity, but only transiently inactivate gastric enzymes. Nonacid reflux, specifically nonacid pepsin, contributes to carcinogenesis in the larynx. Given the carcinogenic potential of pepsin and inefficacy of PPIs to prevent EAC, the presence and effect of pepsin in the esophagus should be investigated.Normal and Barrett's biopsies from 8 Barrett's esophagus patients were collected for pepsin analysis via Western blot and reverse transcriptase-polymerase chain reaction (RT-PCR). Human esophageal cells cultured from healthy patients were treated with pepsin (0.01-1 mg/mL; 1-20 hours), acid (pH 4)±pepsin (5 minutes); real-time RT-PCR, ELISA, and cell migration were assayed.Pepsin was detected in all 8 Barrett's and 4 of 8 adjacent normal specimens. Pepsinogen mRNA was observed in 22 Barrett's, but not in normal adjacent samples. Pepsin induced PTSG2 (COX-2) and IL-1? expression and cell migration in vitro.Pepsin is synthesized by metaplastic, Barrett's esophageal mucosa. Nonacid pepsin increases metrics of tumorigenicity in esophageal epithelial cells in vitro. These findings implicate refluxed and locally synthesized pepsin in development and progression of EAC and, in part, explain the inefficacy of PPIs in the prevention of EAC.

SUBMITTER: Samuels T 

PROVIDER: S-EPMC4750403 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.

Samuels Tina T   Hoekzema Craig C   Gould Jon J   Goldblatt Matthew M   Frelich Matthew M   Bosler Matthew M   Lee Sang-Hyuk SH   Johnston Nikki N  

The Annals of otology, rhinology, and laryngology 20150615 11


<h4>Objective</h4>Despite widespread use of proton pump inhibitors (PPIs), the incidence of esophageal adenocarcinoma (EAC) continues to rise. PPIs reduce reflux acidity, but only transiently inactivate gastric enzymes. Nonacid reflux, specifically nonacid pepsin, contributes to carcinogenesis in the larynx. Given the carcinogenic potential of pepsin and inefficacy of PPIs to prevent EAC, the presence and effect of pepsin in the esophagus should be investigated.<h4>Methods</h4>Normal and Barrett  ...[more]

Similar Datasets

| S-EPMC7710621 | biostudies-literature
| S-EPMC7199943 | biostudies-literature
| S-EPMC2745487 | biostudies-literature
| S-EPMC4596773 | biostudies-literature
| S-EPMC9910260 | biostudies-literature
| S-EPMC9057456 | biostudies-literature
| S-EPMC6025803 | biostudies-literature
| S-EPMC5644061 | biostudies-literature
| S-EPMC6303732 | biostudies-literature
| S-EPMC8417273 | biostudies-literature